According to ER, PgR, HER2 and Ki67 status, tumors were classified as luminal A (ER- and/or PgR-positive, HER2-negative and Ki67 <20%; 40.0%), luminal B (ER- and/or PgR-positive, HER2-negative and Ki67 ≥20%; 22.8%), luminal-HER2 (ER- and/or PgR-positive and HER2-positive; 14.5%), HER2-enriched (ER-negative, PgR-negative, HER2-positive; 9.1%) and triple-negative breast cancer (TNBC, ER/PgR/HER2-negative; 13.6%). The gene discussed is ESR1; the disease is triple-negative breast carcinoma.